Document is current
Any future updates will be listed below
-
Authors
Wang, Jiaojiao
Jin, Jing
Zhang, Mengni
Chen, Xinyuan
Du, Sheng
Mao, Xiaoxiao
Bao, Changlei
Zhu, Jinsheng
Song, Xinyu
Li, Shiyue
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82203883)
Guangzhou fundamental and Basic Fundamental Projects (2025A04J3626)
National Science and Technology Major Project (2024ZD0522600)
Guangdong Key Area R&D Program Key Project (2023B111105006)
- License Information
-
More Information
Article History
Received: 14 July 2025
Accepted: 22 December 2025
First Online: 5 January 2026
Declarations
:
: This study was approved by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Guangzhou Medical University (Approval No. 20240050), the second affiliated institution of the authors. Title of the approved project: Mesenchymal Stem Cell Therapy for Pulmonary Hypertension in Rats: Efficacy and Mechanisms. Date of approval: January 22, 2024. Human bone marrow-derived MSCs were purchased from Cellgenes Cell Biotechnology Co., Ltd (Guangzhou, China), a supplier authorized by the National Institutes for Food and Drug Control (NIFDC, Beijing; Certification No: SH202003514). These cells were derived and quality-controlled accordance with Chinese regulatory standards for clinical researh. No ethics approval was required for the use of these commercially obtained, pro-certified cells.
: All authors confirm their consent for publication.
: The authors declare no competing interests.
